Literature DB >> 12941903

Plasma membrane budding as an alternative release mechanism of the extracellular enveloped form of vaccinia virus from HeLa cells.

Andrea Meiser1, Carmen Sancho, Jacomine Krijnse Locker.   

Abstract

In HeLa cells the assembly of modified vaccinia virus Ankara (MVA), an attenuated vaccinia virus (VV) strain, is blocked. No intracellular mature viruses (IMVs) are made and instead, immature viruses accumulate, some of which undergo condensation and are released from the cell. The condensed particles may undergo wrapping by membranes of the trans-Golgi network and fusion with the plasma membrane prior to their release (M. W. Carroll and B. Moss, Virology 238:198-211, 1997). The present study shows by electron microscopy (EM), however, that the dense particles made in HeLa cells are also released by a budding process at the plasma membrane. By labeling the plasma membrane with antibodies to B5R, a membrane protein of the extracellular enveloped virus, we show that budding occurs at sites that concentrate this protein. EM quantitation revealed that the cell surface around a budding profile was as strongly labeled with anti-B5R antibody as were the extracellular particles, whereas the remainder of the plasma membrane was significantly less labeled. To test whether budding was a characteristic of MVA infection, HeLa cells were infected with the replication competent VV strains Western Reserve strain (WR) and International Health Department strain-J (IHD-J) and also prepared for EM. EM analyses, surprisingly, revealed for both virus strains IMVs that evidently budded at the cell surface at sites that were significantly labeled with anti-B5R. EM also indicated that budding of MVA dense particles was more efficient than budding of IMVs from WR- or IHD-J-infected cells. This was confirmed by semipurifying [(35)S]methionine-labeled dense particles or extracellular enveloped virus (EEVs) from the culture supernatant of MVA- or IHD-J-infected HeLa cells, respectively, showing that threefold more labeled dense particles were secreted than EEVs. Finally, although the released MVA dense particles contain some DNA, they are not infectious, as assessed by plaque assays.

Entities:  

Mesh:

Year:  2003        PMID: 12941903      PMCID: PMC224582          DOI: 10.1128/jvi.77.18.9931-9942.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  27 in total

1.  [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

Authors:  A Mayr; H Stickl; H K Müller; K Danner; H Singer
Journal:  Zentralbl Bakteriol B       Date:  1978-12

2.  Release of vaccinia virus from FL cells infected with the IHD-W strain.

Authors:  K Tsutsui
Journal:  J Electron Microsc (Tokyo)       Date:  1983

3.  Electron microscopic study on vaccinia virus release.

Authors:  K Tsutsui; F Uno; K Akatsuka; S Nii
Journal:  Arch Virol       Date:  1983       Impact factor: 2.574

4.  Morphogenesis and release of fowlpox virus.

Authors:  D Boulanger; T Smith; M A Skinner
Journal:  J Gen Virol       Date:  2000-03       Impact factor: 3.891

5.  A mutation in the gene encoding the vaccinia virus 37,000-M(r) protein confers resistance to an inhibitor of virus envelopment and release.

Authors:  C Schmutz; L G Payne; J Gubser; R Wittek
Journal:  J Virol       Date:  1991-07       Impact factor: 5.103

6.  Significance of extracellular enveloped virus in the in vitro and in vivo dissemination of vaccinia.

Authors:  L G Payne
Journal:  J Gen Virol       Date:  1980-09       Impact factor: 3.891

7.  Nonreplicating vaccinia vector efficiently expresses recombinant genes.

Authors:  G Sutter; B Moss
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-15       Impact factor: 11.205

8.  Brefeldin A inhibits Golgi membrane-catalysed exchange of guanine nucleotide onto ARF protein.

Authors:  J G Donaldson; D Finazzi; R D Klausner
Journal:  Nature       Date:  1992-11-26       Impact factor: 49.962

9.  Identification of the vaccinia hemagglutinin polypeptide from a cell system yielding large amounts of extracellular enveloped virus.

Authors:  L G Payne
Journal:  J Virol       Date:  1979-07       Impact factor: 5.103

10.  Brefeldin A redistributes resident and itinerant Golgi proteins to the endoplasmic reticulum.

Authors:  R W Doms; G Russ; J W Yewdell
Journal:  J Cell Biol       Date:  1989-07       Impact factor: 10.539

View more
  16 in total

1.  Vaccinia virus H2 protein is an essential component of a complex involved in virus entry and cell-cell fusion.

Authors:  Tatiana G Senkevich; Bernard Moss
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

2.  Deletion of major nonessential genomic regions in the vaccinia virus Lister strain enhances attenuation without altering vaccine efficacy in mice.

Authors:  Julie Dimier; Audrey Ferrier-Rembert; Karine Pradeau-Aubreton; Matthias Hebben; Danièle Spehner; Anne-Laure Favier; Danielle Gratier; Daniel Garin; Jean-Marc Crance; Robert Drillien
Journal:  J Virol       Date:  2011-03-02       Impact factor: 5.103

3.  The cellular antiviral restriction factor tetherin does not inhibit poxviral replication.

Authors:  Katja Sliva; Theresa Resch; Benjamin Kraus; Christine Goffinet; Oliver T Keppler; Barbara S Schnierle
Journal:  J Virol       Date:  2011-11-16       Impact factor: 5.103

4.  Vaccinia virus entry into cells is dependent on a virion surface protein encoded by the A28L gene.

Authors:  Tatiana G Senkevich; Brian M Ward; Bernard Moss
Journal:  J Virol       Date:  2004-03       Impact factor: 5.103

Review 5.  Viral use and subversion of membrane organization and trafficking.

Authors:  Miguel Hernandez-Gonzalez; Gabrielle Larocque; Michael Way
Journal:  J Cell Sci       Date:  2021-03-04       Impact factor: 5.285

6.  Monkeypox Virus Host Factor Screen Using Haploid Cells Identifies Essential Role of GARP Complex in Extracellular Virus Formation.

Authors:  Susan Realegeno; Andreas S Puschnik; Amrita Kumar; Cynthia Goldsmith; Jillybeth Burgado; Suryaprakash Sambhara; Victoria A Olson; Darin Carroll; Inger Damon; Tetsuya Hirata; Taroh Kinoshita; Jan E Carette; Panayampalli Subbian Satheshkumar
Journal:  J Virol       Date:  2017-05-12       Impact factor: 6.549

Review 7.  Orthopoxvirus targets for the development of new antiviral agents.

Authors:  Mark N Prichard; Earl R Kern
Journal:  Antiviral Res       Date:  2012-03-08       Impact factor: 10.103

8.  Predicting the subcellular localization of viral proteins within a mammalian host cell.

Authors:  M S Scott; R Oomen; D Y Thomas; M T Hallett
Journal:  Virol J       Date:  2006-04-04       Impact factor: 4.099

9.  A36-dependent actin filament nucleation promotes release of vaccinia virus.

Authors:  Jacquelyn Horsington; Helena Lynn; Lynne Turnbull; Delfine Cheng; Filip Braet; Russell J Diefenbach; Cynthia B Whitchurch; Guna Karupiah; Timothy P Newsome
Journal:  PLoS Pathog       Date:  2013-03-21       Impact factor: 6.823

10.  In vitro host range, multiplication and virion forms of recombinant viruses obtained from co-infection in vitro with a vaccinia-vectored influenza vaccine and a naturally occurring cowpox virus isolate.

Authors:  Malachy Ifeanyi Okeke; Øivind Nilssen; Ugo Moens; Morten Tryland; Terje Traavik
Journal:  Virol J       Date:  2009-05-12       Impact factor: 4.099

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.